AmSurg misses by 2 cents on winter weather

Ambulatory surgery company missed out on 8,000+ procedures
Apr 23, 2014 6:34 AM

Analyst action: AmSurg, Healthways

Veteran analyst Joe France at Cantor Fitzgerald helped give AmSurg shares a pop Wednesday by raising his rating to 'buy' from 'hold.' France sees the second half of this year delivering some positive surprises and has lifted his price target from $42 all the way to $55. AmSurg shares (Ticker: AMSG) were up 3 percent to almost $49 in mid-day action.

Jefferies has begun formally covering shares of Healthways with a 'hold' rating. Analyst David Styblo values the stock at $17, which is 2 percent above where they opened trading (Ticker: HWAY) this morning.

Apr 9, 2014 1:06 PM

Earnings wrap: Emdeon, Symbion

Revenue cycle manager takes charge on project cancellation; surgery center owner ends year with solid case growth
Mar 18, 2014 7:23 AM

In Charge '14: Health care

Mar 2, 2014 1:51 PM

Earnings wrap: AmSurg, Delek Logistics

Surgery center operator guides '14 below consensus; oil infrastructure owner more than doubles operating income
Feb 26, 2014 6:41 AM

Moderate raises for AmSurg execs

Quartet signs new employment agreements
Feb 6, 2014 1:01 PM

BlackRock builds AmSurg stake

Investment giant BlackRock likes the AmSurg story if its latest holdings report is anything go by. At the end of 2013, the firm owned 2.9 million shares of Nashville-based AmSurg, which amounts to 9 percent. A year ago — when AmSurg shares (Ticker: AMSG) were trading more than 30 percent lower than they are now — that stake was 7.8 percent.

Jan 29, 2014 12:18 PM

Analyst action: Delek, AmSurg

Deutsche Bank analyst Paul Sankey has upgraded his rating on shares of Delek US Holdings to 'buy' from 'hold' and hiked his price target to $40 from $30. Sankey, who also upgraded other refining plays, has grown more bullish on the company given the excess supply of light sweet crude. Investor sentiment toward refiners has swung in recent weeks, with Delek (Ticker: DK) popping 30 percent in the past month.

Over at Sidoti, analysts have begun covering shares of AmSurg with a 'neutral' rating and a price target of $48, about $2 above the company's Monday open. AmSurg (Ticker: AMSG) has risen 6 percent in the past month and is up more than 50 percent in 2013.

Dec 10, 2013 6:44 AM

Analyst action: NHI, AmSurg

Analysts at both Stifel Nicolaus and JMP Securities have hiked their rating on shares of National Health Investors to 'buy' from 'hold.' The JMP team now has a price target of $65 on the stock. The real estate investment trust is in the process of buying 25 properties for almost $500 million and both Stifel and JMP are helping manage a stock offering to help fund the deal. NHI shares (Ticker: NHI) ended Monday trading at $59.27 and are up slightly so far this year.

Over at Barclays, analysts have begun covering shares of ambulatory surgery center operator AmSurg. They have rated the stock 'equalweight' and see it climbing about 10 percent to $52. So far this year, AmSurg (Ticker: AMSG) is up more than 50 percent.

Nov 26, 2013 6:57 AM

AmSurg, Healthways execs active in their own stock

Surgery center execs cash in, wellness company officials step up after recent drop
Nov 14, 2013 2:29 PM